Five days. Just as traditional medicines have generics, innovative biological drugs – such as antibodies to fight cancer – have what are known as biosimilars when the original brand loses the patent. Although they are not easy to make. For this reason, the fact that the European Medicines Agency (EMA) has agreed to review the final dossier of the alternative biosimilar to the best-seller Herceptin, from Roche, is crucial news for the pharmaceutical industry.

READ MORE